|Bid||165.78 x 1000|
|Ask||165.82 x 800|
|Day's Range||164.34 - 167.35|
|52 Week Range||144.75 - 179.84|
|Beta (3Y Monthly)||0.76|
|PE Ratio (TTM)||51.14|
|Earnings Date||Jan 29, 2019|
|Forward Dividend & Yield||2.08 (1.27%)|
|1y Target Est||186.18|
Stryker (SYK) announced that it will host a conference call on Tuesday, January 29, 2019 at 4:30 p.m., Eastern Time, to discuss the Company's operating results for the quarter ended December 31, 2018 and provide an operational update. To participate in the conference call dial (866) 393-4306 (domestic) or (734) 385-2616 (international) and be prepared to provide conference ID number 5365367 to the operator. A simultaneous webcast of the call will be accessible via the Company's website at www.stryker.com.
Stryker (SYK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The flip side of that is that there are more Read More...
Stryker (SYK) continues to gain from its Mako robotics platform, which has been the key driver of the company's core Orthopaedic segment.
HENDERSON, NV / ACCESSWIRE / December 17, 2018 / Low back pain is the leading cause of disability in the world and the second most cause of disability in the United States. Degenerative disc disease is one of the most common causes of back pain, affecting more than 3 million people in the US per year. Is estimated that the cost for back pain range from to "at least $50 billion per year" (American Chiropractic Association) to $86 billion per year (WebMD) and to more than $200 billion dollars per year (American Academy of Orthopaedic Surgeons).
The Zacks Analyst Blog Highlights: Walgreens Boots, Duke Energy, Stryker, Kinder Morgan and PepsiCo
Medtronic (MDT) reported net income of $1.1 billion in the second quarter of fiscal 2019 compared to $2.0 billion in the second quarter of fiscal 2018. Medtronic’s net income in the first half of fiscal 2019 totaled $2.2 billion compared to $3.0 billion in the same period the prior year. Wall Street analysts anticipate that Medtronic is expected to report net income of $1.25 billion in the third quarter of fiscal 2019.
Medtronic (MDT) reported net revenues of $7.5 billion in the second quarter of fiscal 2019 compared to $7.1 billion in the second quarter of fiscal 2018, reflecting 6% YoY growth.
Growth at a reasonable price or GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount.
Kalamazoo, Michigan, Dec. 04, 2018 -- Kalamazoo, Michigan – December 4, 2018 – Stryker Corporation (NYSE:SYK) announced that its Board of Directors has declared a quarterly.
Boston Scientific (BSX) stock rose from $24.79 at the close of market on December 29, 2017, to $34.80 at the close of market on November 23, 2018, reflecting a rise of ~40% year-to-date. On November 23, Boston Scientific stock closed at $34.80, a ~42% rise from its 52-week low of $24.54 on December 6, 2017.
Kalamazoo, Michigan, Nov. 27, 2018 -- Stryker (NYSE:SYK) announced today that it has priced the following notes: (i) €550 million aggregate principal amount of the Company’s.
Dentsply Sirona’s (XRAY) interest expense decreased marginally from $9.8 million in the third quarter of 2017 to $9.7 million in the third quarter. The company’s interest income increased from $400,000 in the third quarter of 2017 to $600,000 in the third quarter. Dentsply’s net other expense increased from $900,000 in the third quarter of 2017 to $4.7 million in the third quarter. The company’s provision for income taxes decreased from $7.1 million in the third quarter of 2017 to $4.2 million in the third quarter.
Among the 15 analysts covering Dentsply Sirona (XRAY) in November, five analysts gave a “buy” or a higher recommendation, while ten analysts gave a “hold” recommendation. The mean rating for Dentsply stock is 2.53 with a target price of $46.73, which implies an upside potential of 28% over the closing price of $36.51 on November 23. Peers’ ratings
In November 2018, of the total 20 analysts covering Hologic (HOLX), ten analysts have given the stock a “buy” or higher rating, and ten analysts have given it a “hold” rating. The mean rating for Hologic stock is 2.3 with a target price of $45.09, implying an upside potential of 8.5% over Hologic’s closing price of $41.54 on November 21, 2018.
Hologic’s (HOLX) cost of product revenues increased from $881.8 million in fiscal 2017 to $886.6 million in fiscal 2018. Its amortization on intangible assets increased from $297.1 million in fiscal 2017 to $319.4 million in fiscal 2018 due to an increase associated with the Cynosure acquisition partially offset by lower amortization expenses related to the sale of its blood screening business. The company’s gross margin contracted from 64.07% in fiscal 2017 to 62.72% in fiscal 2018.